These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14735248)

  • 1. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U; Hehlmann R
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract]   [Full Text] [Related]  

  • 2. [Imatinib combination therapies--the new CML Study 4].
    Helmann R; Berger U; Engelich G
    Dtsch Med Wochenschr; 2002 Oct; 127(42):224-6. PubMed ID: 12430568
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
    Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
    Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
    Guilhot F; Druker B; Larson RA; Gathmann I; So C; Waltzman R; O'Brien SG
    Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
    Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
    J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
    Simonsson B; Gedde-Dahl T; Markevärn B; Remes K; Stentoft J; Almqvist A; Björeman M; Flogegård M; Koskenvesa P; Lindblom A; Malm C; Mustjoki S; Myhr-Eriksson K; Ohm L; Räsänen A; Sinisalo M; Själander A; Strömberg U; Bjerrum OW; Ehrencrona H; Gruber F; Kairisto V; Olsson K; Sandin F; Nagler A; Nielsen JL; Hjorth-Hansen H; Porkka K;
    Blood; 2011 Sep; 118(12):3228-35. PubMed ID: 21685374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular response with triple therapy in patients with chronic myeloid leukemia].
    López-Arroyo JL; Rico-Ramos HJ; Portillo-García ML
    Rev Med Inst Mex Seguro Soc; 2014; 52(3):262-5. PubMed ID: 24878083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
    Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller MC; Hehlmann R
    Internist (Berl); 2002 Oct; 43(10):1228, 1231-8, 1241-4. PubMed ID: 12524904
    [No Abstract]   [Full Text] [Related]  

  • 11. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia].
    Turhan A
    Med Sci (Paris); 2003; 19(6-7):667-8. PubMed ID: 12942435
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
    Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate in chronic myeloid leukemia.
    Carella AM; Lerma E
    Curr Stem Cell Res Ther; 2007 Sep; 2(3):249-51. PubMed ID: 18220908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
    O'Dwyer M
    Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.
    Chen X; Yang W; Zhu X
    Pediatr Int; 2011 Aug; 53(4):598-600. PubMed ID: 21851498
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
    Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
    Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
    Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
    Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.